Abstract: The present disclosure provides an enclosure or containment assembly adapted to seal a high pressure fuel rail, and an engine system including such an enclosure or containment assembly. The assembly includes two portions that can sealingly engage to form an enclosure or compartment that contains the high pressure fuel rail. Fuel line connectors leading into the enclosure to ports of the high pressure fuel rail are in a sealing engagement with the enclosure to seal the high pressure fuel rail from the atmosphere and provide an enclosed low pressure region between the high pressure fuel rail and an inner surface of the enclosure. In this way, leaked fuel can be collected from the high pressure fuel lines and contained. The collected and contained leaked fuel can be channeled to a leak detector, which can trigger an alarm with detection of a leak.

Abstract: The present disclosure provides an enclosure or containment assembly adapted to seal a high pressure fuel rail, and an engine system including such an enclosure or containment assembly. The assembly includes two portions that can sealingly engage to form an enclosure or compartment that contains the high pressure fuel rail. Fuel line connectors leading into the enclosure to ports of the high pressure fuel rail are in a sealing engagement with the enclosure to seal the high pressure fuel rail from the atmosphere and provide an enclosed low pressure region between the high pressure fuel rail and an inner surface of the enclosure. In this way, leaked fuel can be collected from the high pressure fuel lines and contained. The collected and contained leaked fuel can be channeled to a leak detector, which can trigger an alarm with detection of a leak.

Abstract: High sparking initiator compositions with a controlled amount of power are disclosed. The initiator compositions comprise a metal containing oxidizing agent, at least one metal reducing agent, and a non-explosive binder. Low voltage igniters that provide bidirectional plumes upon ignition are also disclosed. These igniters have a electrically resistive element positioned across a hole in a support which directs the plume. These igniters and compositions are useful in the actuation of solid fuel heating unit, in particular, sealed heating units.

Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 ?m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Abstract: Described herein are diuretic condensation aerosols and methods of making and using them. Kits for delivering a condensation aerosol are also described. The diuretic aerosols typically comprise diuretic condensation aerosol particles that comprise a diuretic compound. In some variations the diuretic compound is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, muzolimine, spironolactone, torsemide, triamterene, tripamide, BG 9928, and BG 9719. Methods of treating edema using the described aerosols are also provided. In general, the methods typically comprise the step of administering a therapeutically effective amount of diuretic condensation aerosol to a person with edema. The diuretic condensation aerosol may be administered in a single inhalation, or may be administered in more than one inhalation. Methods of forming a diuretic condensation aerosol are also described.

Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 ?m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Abstract: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300° C., and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.

Abstract: An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and 20 ?m. The film thickness is such that an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized compound contains 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The selected substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol. Also disclosed are methods of making and using the article.

Abstract: The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.

Abstract: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

Abstract: Percussive ignition systems and heat packages incorporating percussively igniter systems capable of being activated by inhalation are disclosed.

Abstract: Aerosol drug delivery devices incorporating percussively activated heat packages are disclosed. The heat packages include a percussive igniter and a fuel capable of undergoing an exothermic oxidation-reduction reaction when ignited by the percussive igniter. The drug delivery devices disclosed can be activated by an actuation mechanism to vaporize a thin solid film comprising a drug disposed on the exterior of a hat package. Metal coordination complexes of volatile drugs, and in particular nicotine, from which the drug can be selectively vaporized when heated are also disclosed. The use of aerosol drug delivery devices comprising thin films of nicotine metal salt complexes for the treatment of nicotine craving and for effecting smoking cessation are also disclosed.

Abstract: High sparking initiator compositions with a controlled amount of power are disclosed. The initiator compositions comprise a metal containing oxidizing agent, at least one metal reducing agent, and a non-explosive binder. Low voltage igniters that provide bidirectional plumes upon ignition are also disclosed. These igniters have a electrically resistive element positioned across a hole in a support which directs the plume. These igniters and compositions are useful in the actuation of solid fuel heating unit, in particular, sealed heating units.

Abstract: Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

Abstract: An assembly and method for producing a condensation aerosol are disclosed. The assembly includes a heat-conductive metal substrate with an oxidation resistant exterior surface and a drug composition film on the exterior surface and is for use in an aerosol device. The thickness of the film and the surface of the substrate is such that the aerosol formed by vaporizing and condensing the drug composition the aerosol contain 10% by weight or less drug-degradation products and at least 50% of the total amount of the drug composition in the film. The methods for treating the exterior surface include heat and chemical treatment and formation of a protective overcoat.

Abstract: Methods for determining the film thickness of a compound composition needed to provide a selected purity and yield of a condensation aerosol via vaporization of the compound composition have applications in aerosol delivery technology, in pulmonary drug delivery, and in other therapeutic treatment regimes. The methods for determining such film thickness, for use in a device having a film of drug composition to be aerosolized, include generating purities and yields of a drug composition by vaporizing films of the drug composition from substrates at two or more temperatures in the range of 150° C. to 500° C. and two or more film thickness in the range of 0.05 to 50 microns, determining from these yields and purities if a thickness and temperature exist where the aerosol has at least 90% purity and at least 50% yield, and repeated such measurements until the selected purity and yield requirement are met.